Can’t manage your Crohn’s?
You have options!

Ready to get started? Click Here.

You may qualify for local research studies!

Crohn’s disease is an autoimmune disease that can severely damage parts of the entire digestive tract. Symptoms of Crohn’s vary from one person to the next and may include frequent diarrhea, abdominal pain, fatigue, reduced appetite, unexplained weight loss or fever.

People with Crohn’s disease sometimes experience a period of worsening of symptoms, known as “active” disease or a flare. Flares can interfere with daily activities such as work, family and leisure, causing people to stay at home or only go to places where bathrooms are nearby.

While some people find their symptoms are managed by medications, many others do not find relief. Better treatment options are needed for people who suffer with Crohn’s disease. Right now, local doctors are looking for people who have worsening Crohn’s symptoms to participate in research studies.

If you qualify for one of these research studies, you may receive study-related care from local doctors and specialists with no waiting lists.

There’s no obligation to participate if you call to inquire about the study.

You may qualify for local research studies. But don’t delay — space is limited.

* In a clinical research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. All clinical research studies are approved by SAHPRA and a Research Ethics Committee.

Ready to get started?

Click Here.

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

AcurianHealth

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.